Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Invictus MD Strategies's Enterprise Value is $0.00 Mil.
Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 was $-26.80 Mil. Therefore, Invictus MD Strategies's EV-to-EBIT ratio for today is 0.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Invictus MD Strategies's Enterprise Value is $0.00 Mil.
Invictus MD Strategies's EBITDA for the trailing twelve months (TTM) ended in Oct. 2019 was $-24.87 Mil. Therefore, Invictus MD Strategies's EV-to-EBITDA ratio for today is 0.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Invictus MD Strategies's Enterprise Value is $0.00 Mil.
Invictus MD Strategies's Revenue for the trailing twelve months (TTM) ended in Oct. 2019 was $6.46 Mil. Therefore, Invictus MD Strategies's EV-to-Revenue ratio for today is 0.00.
Invictus MD Strategies Enterprise Value Historical Data
The historical data trend for Invictus MD Strategies's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Invictus MD Strategies's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invictus MD Strategies's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Invictus MD Strategies's Enterprise Value falls into.
Invictus MD Strategies Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Invictus MD Strategies's Enterprise Value for the fiscal year that ended in Jan. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invictus MD Strategies (OTCPK:IVITF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Invictus MD Strategies's current Enterprise Value is $0.00 Mil.
Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.80 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Invictus MD Strategies's EV-to-EBITDA for today is:
Invictus MD Strategies's current Enterprise Value is $0.00 Mil.
Invictus MD Strategies's EBITDA for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.87 Mil.
Invictus MD Strategies's current Enterprise Value is $0.00 Mil.
Invictus MD Strategies's Revenue for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invictus MD Strategies Enterprise Value Related Terms
Thank you for viewing the detailed overview of Invictus MD Strategies's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Invictus MD Strategies (Invictus MD Strategies) Business Description
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IVITF has been successfully added to your 